2026-04-17T14:12:54Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/87772025-10-24T10:17:36Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Serón Micas, Daniel
author
Rabant, Marion
author
Becker, Jan Ulrich
author
Roufosse, Candice
author
Bellini, Maria Irene
author
Böhmig, Georg
2025-10-24T10:17:36Z
2025-10-24T10:17:36Z
2023-01-09T18:19:02Z2023-01-09T18:19:02Z2022-05-20
http://hdl.handle.net/11351/8777
T cell-mediated rejection; Kidney transplantation; OutcomesRebuig mediat per cèl·lules T; Trasplantament renal; ResultatsRechazo mediado por células T; Trasplante renal; ResultadosThe diagnosis of acute T cell-mediated rejection (aTCMR) after kidney transplantation has considerable relevance for research purposes. Its definition is primarily based on tubulointerstitial inflammation and has changed little over time; aTCMR is therefore a suitable parameter for longitudinal data comparisons. In addition, because aTCMR is managed with antirejection therapies that carry additional risks, anxieties, and costs, it is a clinically meaningful endpoint for studies. This paper reviews the history and classifications of TCMR and characterizes its potential role in clinical trials: a role that largely depends on the nature of the biopsy taken (indication vs protocol), the level of inflammation observed (e.g., borderline changes vs full TCMR), concomitant chronic lesions (chronic active TCMR), and the therapeutic intervention planned. There is ongoing variability—and ambiguity—in clinical monitoring and management of TCMR. More research, to investigate the clinical relevance of borderline changes (especially in protocol biopsies) and effective therapeutic strategies that improve graft survival rates with minimal patient morbidity, is urgently required. The present paper was developed from documentation produced by the European Society for Organ Transplantation (ESOT) as part of a Broad Scientific Advice request that ESOT submitted to the European Medicines Agency for discussion in 2020. This paper proposes to move toward refined definitions of aTCMR and borderline changes to be included as primary endpoints in clinical trials of kidney transplantation.This initiative was supported by the European Society for Organ Transplantation.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Ronyons - Trasplantació
Inflamació
Cèl·lules T
Rebuig (Biologia)
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Renal Replacement Therapy::Kidney Transplantation
ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes
PHENOMENA AND PROCESSES::Immune System Phenomena::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection
DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento de reemplazo renal::trasplante de riñón
ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T
FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunología del trasplante::reacción huésped contra injerto::rechazo del injerto
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación
Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion